White Papers

White Papers

Reducing Risk For Commercial Manufacturing Of Cell And Gene Therapies Reducing Risk For Commercial Manufacturing Of Cell And Gene Therapies

White Paper

The Use of a Proven AAV Platform to Drive Down Program Costs and Maximize Speed The Use of a Proven AAV Platform to Drive Down Program Costs and Maximize Speed

White Paper

Partnering for Scalable Suspension Processes Tailored to AAV Gene Therapies Partnering for Scalable Suspension Processes Tailored to AAV Gene Therapies

White Paper

In-House Plasmid Production to Secure Supply Chains In-House Plasmid Production to Secure Supply Chains

White Paper

The Future of Viral Vector Manufacturing: Yield Optimization The Future of Viral Vector Manufacturing: Yield Optimization

White Paper

Early Plasmid Optimization For Long-Term Commercial Success Early Plasmid Optimization For Long-Term Commercial Success

White Paper

DMF Update DMF Update

White Paper

Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing

White Paper

Leveraging Partnerships and a Unique History to Address Supply Chain Leveraging Partnerships and a Unique History to Address Supply Chain

White Paper

Coping with a Talent Shortage and Talent War in Cell and Gene Therapy Coping with a Talent Shortage and Talent War in Cell and Gene Therapy

White Paper

By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Preferences Deny Accept